Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, First-in-human, Single Agent, Dose-escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442085 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04000282 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04000282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04000282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, First-in-human, Single Agent, Dose-escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442085 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
August 19, 2019
Completion date
September 4, 2023
Enrollment
37 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma